Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
← Назад к работе

Работы, на которые ссылается эта работа

Работ: 361

Работа: Epigenetic mechanisms and next-gen editing platforms in hematology: From molecular basis to therapeutic frontiers

  1. Unveiling the potential of CLL-1: a promising target for AML therapy

    Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Hamideh Rahmani Seraji +4

    Обзорная статья2025Цитирований: 6
    ABI
  2. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu, David Marín, Pinaki P. Banerjee +24

    Статья2020Цитирований: 6
    ABI
  3. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression

    Lei S. Qi, Matthew H. Larson, Luke A. Gilbert +4

    Статья2013Цитирований: 3
    ABI
  4. Delivering CRISPR: a review of the challenges and approaches

    Christopher A. Lino, Jason C. Harper, James P. Carney +1

    Обзорная статья2018Цитирований: 3
    ABI
  5. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

    Статья2018Цитирований: 3
    ABI
  6. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Статья2018Цитирований: 3
    ABI
  7. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

    Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu +3

    Обзорная статья2022Цитирований: 3
    ABI
  8. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

    Yanfang Fu, Jennifer A Foden, Cyd Khayter +4

    Статья2013Цитирований: 2
    ABI
  9. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage

    Nicole M. Gaudelli, Alexis C. Komor, Holly A. Rees +4

    Статья2017Цитирований: 2
    ABI
  10. The CRISPR tool kit for genome editing and beyond

    Mazhar Adli

    Обзорная статья2018Цитирований: 2
    ABI
  11. CRISPR-engineered T cells in patients with refractory cancer

    Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

    Статья2020Цитирований: 2
    ABI
  12. Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

    Rajkumar Prabhakaran, Rajkumar Thamarai, Sivabalan Sivasamy +6

    Обзорная статья2024Цитирований: 2
    ABI
  13. “Galectin-9: A double-edged sword in Acute Myeloid Leukemia”

    Omolbanin Sargazi-Aval, Ali Ahmadi, Ali Jihad Hemid Al-Athari +5

    Обзорная статья2025Цитирований: 2
    ABI
  14. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia

    Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Sajjad Peyvasteh +1

    Обзорная статья2025Цитирований: 2
    ABI
  15. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation

    Ashok Kumar Bishoyi, Sina Nouri, Ahmed Hussen +3

    Обзорная статья2025Цитирований: 2
    ABI
  16. Non-homologous DNA end joining and alternative pathways to double-strand break repair

    Howard H. Chang, Nicholas R. Pannunzio, Noritaka Adachi +1

    Обзорная статья2017Цитирований: 2
    ABI
  17. Epigenetic Therapeutics: A New Weapon in the War Against Cancer

    Nita Ahuja, Anup Sharma, Stephen B. Baylin

    Обзорная статья2016Цитирований: 2
    ABI